Reference table

The nomination tracker

What became of each peptide's nomination to the 503A bulks list?

The answer

Seven dispositions account for every molecule in this index, and the two most often reported as approvals — removal from Category 2 without listing, and withdrawal by the nominators — are the opposite of one.

By Peptide America · Publisher · Reviewed October 2026

A peptide reaches a pharmacy's shelf through a nomination: a party asks the FDA to place a bulk substance on the section 503A list, and the agency sorts the nomination while it reviews. The sorting has more than two outcomes, and the outcomes that are neither a listing nor a prohibition are the ones the market misreads.

This tracker files each molecule by what actually became of its nomination, with the ledger entry that establishes the disposition beside it.

Denominator

The counts below are counts of the substances this index tracks, and nothing more. They are not a total of all peptides nominated to the 503A bulks list; no source this index has verified states such a total, so this page does not print one.

Rows are read from MOLECULES[].status, MOLECULES[].statusLine, MOLECULES[].record[] — the same dated ledger the molecule index renders. No cell on this page is typed by hand.

Molecule	Disposition	US status	What the record states
Tesamorelin	Approved drug product; no bulks nomination required	FDA-approved	March 2025. FDA approves EGRIFTA WR, an eight-fold concentrated formulation reconstituted weekly rather than daily; it replaces EGRIFTA SV.
Semaglutide	Approved drug product; no bulks nomination required	FDA-approved	April 2026. FDA proposes excluding semaglutide from the 503B bulks list, closing the outsourcing-facility route; patient-specific 503A compounding requires a documented clinical need an approved product cannot meet.
Tirzepatide	Approved drug product; no bulks nomination required	FDA-approved	April 2026. FDA proposes excluding tirzepatide from the 503B bulks list; the lawful remainder is patient-specific 503A compounding with documented clinical need.
Setmelanotide	Approved drug product; no bulks nomination required	FDA-approved	September 2026. Setmelanotide sits in no category of the 503A bulks list published May 14, 2026 and on no 503B list. An approved product exists, so the question the bulks list answers does not arise for it.
PT-141	Approved drug product; no bulks nomination required	FDA-approved	August 2026. The product remains marketed under a new labeler and is recorded as prescription-only in Drugs@FDA. Bremelanotide sits in no category of the 503A bulks list published May 14, 2026 and on no 503B list.
Liraglutide	Approved drug product; no bulks nomination required	FDA-approved	August 2026. The shortage entry still reads currently in shortage. Two generic manufacturers report both presentations available; the brand manufacturer reports limited availability, with Saxenda 6 mg/mL available until discontinuation in January 2027 and Victoza 6 mg/mL delayed in shipping with no estimated duration.
Elamipretide	Approved drug product; no bulks nomination required	FDA-approved	September 2026. Elamipretide appears in none of the three categories of the 503A bulks list published May 14, 2026; that list files substances nominated for compounding, and a marketed product supplies this one. FDA's drug shortage database holds no entry for it.
Afamelanotide	Approved drug product; no bulks nomination required	FDA-approved	September 2026. Neither afamelanotide nor the name melanotan appears in any of the three categories of the 503A bulks list published May 14, 2026; that list files substances nominated for compounding, and a marketed product supplies this one.
Dulaglutide	Approved drug product; no bulks nomination required	FDA-approved	September 2026. Dulaglutide appears in none of the three categories of the 503A bulks list published May 14, 2026; that list files substances nominated for compounding, and a licensed biologic is supplied by its own manufacturer. FDA's drug shortage database holds no entry for it, in a query whose control on liraglutide returned eleven records with the status Current.
Sermorelin	Category 1 of the interim 503A bulks list	Compoundable (503A)	August 2026. Compounded by 503A pharmacies with a valid prescription; the discontinued approval was withdrawn for commercial, not safety, reasons.
NAD+	Category 1 of the interim 503A bulks list	Compoundable (503A)	August 2026. Listed in Category 1 of the interim 503A bulks list; pharmacies may compound while FDA review continues.
Glutathione	Category 1 of the interim 503A bulks list	Compoundable (503A)	August 2026. Listed in Category 1 of the interim 503A bulks list; pharmacies may compound while FDA review continues.
GHK-Cu	Category 1 of the interim 503A bulks list	Compoundable (503A)	April 2026. FDA removes GHK-Cu from Category 1 of the interim 503A bulks list on April 22, 2026, the nominations withdrawn by the nominators. GHK-Cu was not among the seven peptides reviewed at the July 2026 PCAC meeting.
Vasoactive intestinal peptide	Category 1 of the interim 503A bulks list	Compoundable (503A)	September 2026. Drugs@FDA holds no approved product with vasoactive intestinal peptide or aviptadil as an active ingredient. The lawful route to a patient is therefore a pharmacy preparation under section 503A, not a manufactured product, and the difference decides what quality obligations attach.
Kisspeptin-10	Category 2 of the interim 503A bulks list; compounding barred	No lawful route	August 2026. Kisspeptin-10 remains in Category 2 of the 503A list published May 14, 2026, and is the only peptide among the six substances in that category. Placement in Category 2 bars a licensed pharmacy from compounding the substance.
GHRP-2	Category 3 of the interim 503A bulks list; nominated without adequate support	No lawful route	September 2026. Drugs@FDA holds no approved product with GHRP-2 or pralmorelin as an active ingredient, and the substance was not among the seven peptides the advisory committee reviewed in July 2026. Its position is therefore unchanged by the 2026 meeting.
GHRP-6	Category 3 of the interim 503A bulks list; nominated without adequate support	No lawful route	September 2026. Drugs@FDA holds no approved product with GHRP-6 as an active ingredient, and the substance was not among the seven peptides the advisory committee reviewed in July 2026.
Mechano growth factor	Category 3 of the interim 503A bulks list; nominated without adequate support	No lawful route	September 2026. Drugs@FDA holds no approved product with mechano growth factor as an active ingredient, and neither form was among the seven peptides the advisory committee reviewed in July 2026. Two forms of one molecule therefore hold two different dispositions and the same absence of a lawful route.
ARA-290	Category 3 of the interim 503A bulks list; nominated without adequate support	No lawful route	September 2026. Drugs@FDA holds no approved product with cibinetide as an active ingredient, and the substance was not among the seven peptides the advisory committee reviewed in July 2026.
Secretin	Category 3 of the interim 503A bulks list; nominated without adequate support	FDA-approved	May 2026. The section 503A bulks list published May 14, 2026 lists Secretin, human 99% in Category 3, the file for substances nominated without adequate support to evaluate. A bulk nomination for a substance that is already the active ingredient of an approved product raises the essentially-a-copy question that section 503A exists to control.
Thymulin	Category 3 of the interim 503A bulks list; nominated without adequate support	No lawful route	September 2026. Drugs@FDA holds no approved product with thymulin as an active ingredient, and the substance was not among the seven peptides the advisory committee reviewed in July 2026.
L-carnosine	Category 3 of the interim 503A bulks list; nominated without adequate support	No lawful route	September 2026. Drugs@FDA holds no approved product with carnosine as an active ingredient, and the substance was not among the seven peptides the advisory committee reviewed in July 2026. It is lawfully sold as a dietary supplement, which is a separate regulatory regime carrying its own and much lower evidentiary threshold.
BPC-157	Removed from Category 2 without listing	PCAC-recommended · pending	April 2026. FDA removes BPC-157 and eleven other peptides from Category 2 without adding them to Category 1; the removal ends the explicit prohibition but confers no authorization.
MOTS-c	Removed from Category 2 without listing	PCAC-recommended · pending	April 2026. Removed from Category 2 without Category 1 listing.
TB-500	Removed from Category 2 without listing	PCAC-recommended · pending	April 2026. Removed from Category 2 without Category 1 listing.
KPV	Removed from Category 2 without listing	PCAC-recommended · pending	April 2026. Removed from Category 2 without Category 1 listing.
Semax	Removed from Category 2 without listing	PCAC-recommended · pending	April 2026. Removed from Category 2 without Category 1 listing.
Epitalon	Removed from Category 2 without listing	PCAC-recommended · pending	April 2026. Removed from Category 2 without Category 1 listing.
DSIP	Removed from Category 2 without listing	No lawful route	April 2026. Removed from Category 2 without Category 1 listing.
Melanotan II	Removed from Category 2 without listing	No lawful route	August 2026. FDA still publishes its Category 2 safety finding for the substance among those nominated but withdrawn: compounded drugs containing Melanotan II may pose a risk for immunogenicity, and published case reports discuss melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. The withdrawal removed the substance from the category; it did not retract the finding.
LL-37	Removed from Category 2 without listing	No lawful route	August 2026. FDA continues to publish the safety finding: it lacks sufficient safety-related information to know whether the drug would cause harm when administered to humans, and nonclinical research findings suggest detrimental effects on male reproduction and that the drug can be pro-tumorigenic in some tissues.
Dihexa	Removed from Category 2 without listing	No lawful route	August 2026. FDA continues to publish its finding for the substance: it has not identified any human exposure data on drug products containing dihexa acetate administered via any route of administration, and it lacks important information regarding any safety issues raised by the substance, including whether it would cause harm if administered to humans.
PEG-MGF	Removed from Category 2 without listing	No lawful route	August 2026. On the list FDA published May 14, 2026, PEG-MGF appears in no category, while the unpegylated substance — mechano growth factor (MGF) — appears in Category 3, the category for substances nominated without adequate support. FDA's published finding for PEG-MGF is that it has identified no human exposure data on drug products containing it by any route.
CJC-1295	Nomination withdrawn by its nominators	Nomination withdrawn	September 2024. Removed from Category 2 after nominator withdrawal; not added to Category 1.
Ipamorelin	Nomination withdrawn by its nominators	Nomination withdrawn	September 2024. The nominators withdraw their nominations of ipamorelin acetate and ipamorelin free base for the section 503A bulks list on September 19, 2024. FDA later files ipamorelin acetate among the substances previously in 503A Category 2 whose nominations were withdrawn.
AOD-9604	Nomination withdrawn by its nominators	Nomination withdrawn	August 2026. AOD-9604 appears in FDA's table of substances nominated but withdrawn and in no category of the 503A list published May 14, 2026. FDA's published finding notes serious adverse events that may be associated with the substance, though causality is not clear.
Thymosin alpha-1	Nomination withdrawn by its nominators	Nomination withdrawn	August 2026. Thymosin alpha-1 appears in FDA's table of substances nominated but withdrawn, in no category of the 503A list published May 14, 2026, and in Category 3 of the 503B list — nominated without adequate support. No FDA-approved product containing it exists.
Selank	Nomination withdrawn by its nominators	Nomination withdrawn	August 2026. Selank acetate (TP-7) appears in FDA's table of substances nominated but withdrawn and in no category of the 503A list published May 14, 2026. FDA's published finding is that it lacks important information regarding any safety issues raised by selank acetate administered to humans.
Cerebrolysin	Never nominated	No lawful route	September 2026. Cerebrolysin appears in no category of the section 503A bulks list published May 14, 2026, in none of the tables on FDA's Category 2 safety-risk page, and nowhere on the section 503B nominations list. Drugs@FDA holds no application for it under any name.
Retatrutide	Never nominated	No lawful route	August 2026. Drugs@FDA holds no record of retatrutide as the active ingredient of any drug product, and the substance sits in no category of the 503A bulks list published May 14, 2026 and on no 503B list. It has never been nominated for one.

MoleculeTesamorelin
DispositionApproved drug product; no bulks nomination required
US statusFDA-approved
What the record statesMarch 2025. FDA approves EGRIFTA WR, an eight-fold concentrated formulation reconstituted weekly rather than daily; it replaces EGRIFTA SV.
MoleculeSemaglutide
DispositionApproved drug product; no bulks nomination required
US statusFDA-approved
What the record statesApril 2026. FDA proposes excluding semaglutide from the 503B bulks list, closing the outsourcing-facility route; patient-specific 503A compounding requires a documented clinical need an approved product cannot meet.
MoleculeTirzepatide
DispositionApproved drug product; no bulks nomination required
US statusFDA-approved
What the record statesApril 2026. FDA proposes excluding tirzepatide from the 503B bulks list; the lawful remainder is patient-specific 503A compounding with documented clinical need.
MoleculeSetmelanotide
DispositionApproved drug product; no bulks nomination required
US statusFDA-approved
What the record statesSeptember 2026. Setmelanotide sits in no category of the 503A bulks list published May 14, 2026 and on no 503B list. An approved product exists, so the question the bulks list answers does not arise for it.
MoleculePT-141
DispositionApproved drug product; no bulks nomination required
US statusFDA-approved
What the record statesAugust 2026. The product remains marketed under a new labeler and is recorded as prescription-only in Drugs@FDA. Bremelanotide sits in no category of the 503A bulks list published May 14, 2026 and on no 503B list.
MoleculeLiraglutide
DispositionApproved drug product; no bulks nomination required
US statusFDA-approved
What the record statesAugust 2026. The shortage entry still reads currently in shortage. Two generic manufacturers report both presentations available; the brand manufacturer reports limited availability, with Saxenda 6 mg/mL available until discontinuation in January 2027 and Victoza 6 mg/mL delayed in shipping with no estimated duration.
MoleculeElamipretide
DispositionApproved drug product; no bulks nomination required
US statusFDA-approved
What the record statesSeptember 2026. Elamipretide appears in none of the three categories of the 503A bulks list published May 14, 2026; that list files substances nominated for compounding, and a marketed product supplies this one. FDA's drug shortage database holds no entry for it.
MoleculeAfamelanotide
DispositionApproved drug product; no bulks nomination required
US statusFDA-approved
What the record statesSeptember 2026. Neither afamelanotide nor the name melanotan appears in any of the three categories of the 503A bulks list published May 14, 2026; that list files substances nominated for compounding, and a marketed product supplies this one.
MoleculeDulaglutide
DispositionApproved drug product; no bulks nomination required
US statusFDA-approved
What the record statesSeptember 2026. Dulaglutide appears in none of the three categories of the 503A bulks list published May 14, 2026; that list files substances nominated for compounding, and a licensed biologic is supplied by its own manufacturer. FDA's drug shortage database holds no entry for it, in a query whose control on liraglutide returned eleven records with the status Current.
MoleculeSermorelin
DispositionCategory 1 of the interim 503A bulks list
US statusCompoundable (503A)
What the record statesAugust 2026. Compounded by 503A pharmacies with a valid prescription; the discontinued approval was withdrawn for commercial, not safety, reasons.
MoleculeNAD+
DispositionCategory 1 of the interim 503A bulks list
US statusCompoundable (503A)
What the record statesAugust 2026. Listed in Category 1 of the interim 503A bulks list; pharmacies may compound while FDA review continues.
MoleculeGlutathione
DispositionCategory 1 of the interim 503A bulks list
US statusCompoundable (503A)
What the record statesAugust 2026. Listed in Category 1 of the interim 503A bulks list; pharmacies may compound while FDA review continues.
MoleculeGHK-Cu
DispositionCategory 1 of the interim 503A bulks list
US statusCompoundable (503A)
What the record statesApril 2026. FDA removes GHK-Cu from Category 1 of the interim 503A bulks list on April 22, 2026, the nominations withdrawn by the nominators. GHK-Cu was not among the seven peptides reviewed at the July 2026 PCAC meeting.
MoleculeVasoactive intestinal peptide
DispositionCategory 1 of the interim 503A bulks list
US statusCompoundable (503A)
What the record statesSeptember 2026. Drugs@FDA holds no approved product with vasoactive intestinal peptide or aviptadil as an active ingredient. The lawful route to a patient is therefore a pharmacy preparation under section 503A, not a manufactured product, and the difference decides what quality obligations attach.
MoleculeKisspeptin-10
DispositionCategory 2 of the interim 503A bulks list; compounding barred
US statusNo lawful route
What the record statesAugust 2026. Kisspeptin-10 remains in Category 2 of the 503A list published May 14, 2026, and is the only peptide among the six substances in that category. Placement in Category 2 bars a licensed pharmacy from compounding the substance.
MoleculeGHRP-2
DispositionCategory 3 of the interim 503A bulks list; nominated without adequate support
US statusNo lawful route
What the record statesSeptember 2026. Drugs@FDA holds no approved product with GHRP-2 or pralmorelin as an active ingredient, and the substance was not among the seven peptides the advisory committee reviewed in July 2026. Its position is therefore unchanged by the 2026 meeting.
MoleculeGHRP-6
DispositionCategory 3 of the interim 503A bulks list; nominated without adequate support
US statusNo lawful route
What the record statesSeptember 2026. Drugs@FDA holds no approved product with GHRP-6 as an active ingredient, and the substance was not among the seven peptides the advisory committee reviewed in July 2026.
MoleculeMechano growth factor
DispositionCategory 3 of the interim 503A bulks list; nominated without adequate support
US statusNo lawful route
What the record statesSeptember 2026. Drugs@FDA holds no approved product with mechano growth factor as an active ingredient, and neither form was among the seven peptides the advisory committee reviewed in July 2026. Two forms of one molecule therefore hold two different dispositions and the same absence of a lawful route.
MoleculeARA-290
DispositionCategory 3 of the interim 503A bulks list; nominated without adequate support
US statusNo lawful route
What the record statesSeptember 2026. Drugs@FDA holds no approved product with cibinetide as an active ingredient, and the substance was not among the seven peptides the advisory committee reviewed in July 2026.
MoleculeSecretin
DispositionCategory 3 of the interim 503A bulks list; nominated without adequate support
US statusFDA-approved
What the record statesMay 2026. The section 503A bulks list published May 14, 2026 lists Secretin, human 99% in Category 3, the file for substances nominated without adequate support to evaluate. A bulk nomination for a substance that is already the active ingredient of an approved product raises the essentially-a-copy question that section 503A exists to control.
MoleculeThymulin
DispositionCategory 3 of the interim 503A bulks list; nominated without adequate support
US statusNo lawful route
What the record statesSeptember 2026. Drugs@FDA holds no approved product with thymulin as an active ingredient, and the substance was not among the seven peptides the advisory committee reviewed in July 2026.
MoleculeL-carnosine
DispositionCategory 3 of the interim 503A bulks list; nominated without adequate support
US statusNo lawful route
What the record statesSeptember 2026. Drugs@FDA holds no approved product with carnosine as an active ingredient, and the substance was not among the seven peptides the advisory committee reviewed in July 2026. It is lawfully sold as a dietary supplement, which is a separate regulatory regime carrying its own and much lower evidentiary threshold.
MoleculeBPC-157
DispositionRemoved from Category 2 without listing
US statusPCAC-recommended · pending
What the record statesApril 2026. FDA removes BPC-157 and eleven other peptides from Category 2 without adding them to Category 1; the removal ends the explicit prohibition but confers no authorization.
MoleculeMOTS-c
DispositionRemoved from Category 2 without listing
US statusPCAC-recommended · pending
What the record statesApril 2026. Removed from Category 2 without Category 1 listing.
MoleculeTB-500
DispositionRemoved from Category 2 without listing
US statusPCAC-recommended · pending
What the record statesApril 2026. Removed from Category 2 without Category 1 listing.
MoleculeKPV
DispositionRemoved from Category 2 without listing
US statusPCAC-recommended · pending
What the record statesApril 2026. Removed from Category 2 without Category 1 listing.
MoleculeSemax
DispositionRemoved from Category 2 without listing
US statusPCAC-recommended · pending
What the record statesApril 2026. Removed from Category 2 without Category 1 listing.
MoleculeEpitalon
DispositionRemoved from Category 2 without listing
US statusPCAC-recommended · pending
What the record statesApril 2026. Removed from Category 2 without Category 1 listing.
MoleculeDSIP
DispositionRemoved from Category 2 without listing
US statusNo lawful route
What the record statesApril 2026. Removed from Category 2 without Category 1 listing.
MoleculeMelanotan II
DispositionRemoved from Category 2 without listing
US statusNo lawful route
What the record statesAugust 2026. FDA still publishes its Category 2 safety finding for the substance among those nominated but withdrawn: compounded drugs containing Melanotan II may pose a risk for immunogenicity, and published case reports discuss melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. The withdrawal removed the substance from the category; it did not retract the finding.
MoleculeLL-37
DispositionRemoved from Category 2 without listing
US statusNo lawful route
What the record statesAugust 2026. FDA continues to publish the safety finding: it lacks sufficient safety-related information to know whether the drug would cause harm when administered to humans, and nonclinical research findings suggest detrimental effects on male reproduction and that the drug can be pro-tumorigenic in some tissues.
MoleculeDihexa
DispositionRemoved from Category 2 without listing
US statusNo lawful route
What the record statesAugust 2026. FDA continues to publish its finding for the substance: it has not identified any human exposure data on drug products containing dihexa acetate administered via any route of administration, and it lacks important information regarding any safety issues raised by the substance, including whether it would cause harm if administered to humans.
MoleculePEG-MGF
DispositionRemoved from Category 2 without listing
US statusNo lawful route
What the record statesAugust 2026. On the list FDA published May 14, 2026, PEG-MGF appears in no category, while the unpegylated substance — mechano growth factor (MGF) — appears in Category 3, the category for substances nominated without adequate support. FDA's published finding for PEG-MGF is that it has identified no human exposure data on drug products containing it by any route.
MoleculeCJC-1295
DispositionNomination withdrawn by its nominators
US statusNomination withdrawn
What the record statesSeptember 2024. Removed from Category 2 after nominator withdrawal; not added to Category 1.
MoleculeIpamorelin
DispositionNomination withdrawn by its nominators
US statusNomination withdrawn
What the record statesSeptember 2024. The nominators withdraw their nominations of ipamorelin acetate and ipamorelin free base for the section 503A bulks list on September 19, 2024. FDA later files ipamorelin acetate among the substances previously in 503A Category 2 whose nominations were withdrawn.
MoleculeAOD-9604
DispositionNomination withdrawn by its nominators
US statusNomination withdrawn
What the record statesAugust 2026. AOD-9604 appears in FDA's table of substances nominated but withdrawn and in no category of the 503A list published May 14, 2026. FDA's published finding notes serious adverse events that may be associated with the substance, though causality is not clear.
MoleculeThymosin alpha-1
DispositionNomination withdrawn by its nominators
US statusNomination withdrawn
What the record statesAugust 2026. Thymosin alpha-1 appears in FDA's table of substances nominated but withdrawn, in no category of the 503A list published May 14, 2026, and in Category 3 of the 503B list — nominated without adequate support. No FDA-approved product containing it exists.
MoleculeSelank
DispositionNomination withdrawn by its nominators
US statusNomination withdrawn
What the record statesAugust 2026. Selank acetate (TP-7) appears in FDA's table of substances nominated but withdrawn and in no category of the 503A list published May 14, 2026. FDA's published finding is that it lacks important information regarding any safety issues raised by selank acetate administered to humans.
MoleculeCerebrolysin
DispositionNever nominated
US statusNo lawful route
What the record statesSeptember 2026. Cerebrolysin appears in no category of the section 503A bulks list published May 14, 2026, in none of the tables on FDA's Category 2 safety-risk page, and nowhere on the section 503B nominations list. Drugs@FDA holds no application for it under any name.
MoleculeRetatrutide
DispositionNever nominated
US statusNo lawful route
What the record statesAugust 2026. Drugs@FDA holds no record of retatrutide as the active ingredient of any drug product, and the substance sits in no category of the 503A bulks list published May 14, 2026 and on no 503B list. It has never been nominated for one.

A withdrawn nomination is the disposition with the least written about it and the most misread; CJC-1295's withdrawal sets out what happened and what it left behind. The research-only page covers both routes into that position, and what removal does not mean covers the other.

Elsewhere in this index

Other tables

The July 2026 vote ledgerHow did the advisory committee vote on each peptide, and what does a vote do?
The 2026 recordWhat happened to United States peptide compounding law in 2026, in order?
Removal is not permissionThe peptides removed from Category 2 in April 2026 — are they lawful now?
Approved peptide drugsWhich peptides in this index are actually approved drugs?
The human trial record, by moleculeHow many human clinical trials exist for each peptide in this index?
The WADA Prohibited ListWhich peptides in this index are prohibited in sport, and under which class?
Final-action watchHas the FDA finalized anything on the peptides recommended in July 2026?

Evidence reviews

Peptides for Weight Loss, by US Legal StatusWhich peptides sold for weight loss are actually FDA-approved for it?
Sermorelin vs Tesamorelin: How They DifferHow do sermorelin and tesamorelin differ?
Tesamorelin Side Effects: What the Label SaysWhat side effects does the tesamorelin label record?
Tesamorelin: Approved Drug, Sold PeptideDoes the evidence behind tesamorelin's approval support general fat loss?
Semaglutide Withdrawal: Weight Regain EvidenceHow much weight returns after stopping semaglutide?
Dulaglutide vs Semaglutide: Trial ResultsWhat does the dulaglutide-versus-semaglutide evidence actually compare?
Incretin Pipeline: Retatrutide and CagriSemaWhich incretin drugs are approved, which are still in trials, and which of them are peptides?
Tirzepatide: Sleep Apnea Trial EvidenceDoes tirzepatide treat sleep apnea or only reduce weight?
Setmelanotide: Who Lost Weight in Trials?Can setmelanotide trial results predict general weight loss?
Bremelanotide: Desire and Distress TrialsWhat did bremelanotide improve in the RECONNECT trials?
PT-141: The Approval Buyers Do Not Know AboutWhat is PT-141's actual United States posture, and what does its approval cover?
Elamipretide for Fatigue: Trial ResultsDoes elamipretide improve fatigue and exercise capacity?
Afamelanotide: Light Tolerance EvidenceWhat did afamelanotide trials actually measure?
Melanotan I vs II: One Approved, One NotWhat is the difference between Melanotan I and Melanotan II?
Retatrutide and Lean Mass: Trial EvidenceDoes retatrutide preserve muscle while reducing body fat?
CJC-1295 With Ipamorelin: The EvidenceWhat is known about CJC-1295 taken with ipamorelin?
Sermorelin: The Trial Record Stopped in 2005Does sermorelin produce the effects attributed to growth hormone therapy?
NAD+ Infusions and the Precursor TrialsDo the nicotinamide riboside and nicotinamide mononucleotide trials support intravenous NAD+?
Glutathione Injections for Skin LighteningIs injectable glutathione established for skin lightening, and what has the FDA said about it?
GLOW and KLOW Peptide Blends: What Is in ThemWhat are the GLOW and KLOW peptide blends, and has either been tested in people?
GHK-Cu: Topical Evidence, Injectable SalesDoes the cosmetic-science evidence for copper tripeptide support injecting it?
Aviptadil for COVID-19: Trial ResultsDid aviptadil improve outcomes in severe COVID-19?
A Lawful Peptide Is Not a Proven OneDoes a lawful compounding status mean a peptide is supported by evidence?
Kisspeptin-10 and Testosterone: EvidenceDoes kisspeptin-10 treat low testosterone?
Category 3: Nominated, Not ReviewedWhat does Category 3 of the FDA 503A bulks list actually mean?
What the GHRP Trial Records MeasureDo the trial records for GHRP-2 and GHRP-6 support the uses the compounds are sold for?
ARA-290 for Neuropathy: Trial FindingsDoes ARA-290 have convincing evidence for neuropathic pain?
Secretin for Autism: A Closed QuestionDid the randomized trials of secretin for autism support the treatment?
Thymulin's Eight Trials Measure ZincDo thymulin's eight trial-type records show that the peptide has been tested in people?
Carnosine: Glucose and Vascular EvidenceWhy do carnosine studies report positive and negative metabolic results?
BPC-157 Oral and Nasal: What the Record ShowsDoes BPC-157 work when taken by mouth or as a nasal spray, and how do those forms compare with injection?
BPC-157 Side Effects: The Safety RecordWhat are the side effects of BPC-157, and what is actually known about its safety?
The Wolverine Stack: BPC-157 With TB-500What is the Wolverine stack, and has BPC-157 with TB-500 been tested in people?
BPC-157: No Controlled Human Trial on RecordHas BPC-157 ever been tested in a human clinical trial?
MOTS-c: Mitochondria, No Human OutcomesDoes MOTS-c do in people what the exercise-mimetic marketing claims?
TB-500 Is Not Thymosin Beta-4Does the published thymosin beta-4 research apply to the compound sold as TB-500?
KPV: What Has Been Tested in PeopleWhat human evidence exists for KPV?
Semax vs Selank: Two Russian Peptides ComparedHow do Semax and Selank differ, and what is the evidence and legal status of each?
Semax: A Russian Drug, Unapproved HereWhat supports Semax as a nootropic, and what is its United States posture?
Epitalon and the Lifespan ClaimsDoes the evidence support the lifespan and telomerase claims made for Epitalon?
DSIP: The Committee's Only RejectionWhy was DSIP the only peptide the July 2026 committee refused to recommend?
Melanotan II: The Record on a Tanning PeptideWhat is the record on Melanotan II, which was removed from Category 2 and never reviewed?
LL-37 Wound Healing: What Trials FoundDo LL-37 wound studies establish that the peptide works?
CJC-1295: A Withdrawal, Not a ClearanceWhy did CJC-1295 leave Category 2 in September 2024, and what is its status now?
Ipamorelin's One Trial Missed Its EndpointWhat did the one randomized controlled trial of ipamorelin find?
Thymosin Alpha-1: Sepsis Trial ResultsDoes thymosin alpha-1 improve survival in sepsis?
Cerebrolysin After Stroke: Mixed EvidenceWhy do Cerebrolysin stroke trials appear to disagree?

Monographs in this table

TesamorelinFDA-approved
SemaglutideFDA-approved
TirzepatideFDA-approved
SetmelanotideFDA-approved
PT-141FDA-approved
LiraglutideFDA-approved
ElamipretideFDA-approved
AfamelanotideFDA-approved
DulaglutideFDA-approved
SermorelinCompoundable (503A)
NAD+Compoundable (503A)
GlutathioneCompoundable (503A)
GHK-CuCompoundable (503A)
Vasoactive intestinal peptideCompoundable (503A)
Kisspeptin-10No lawful route
GHRP-2No lawful route
GHRP-6No lawful route
Mechano growth factorNo lawful route
ARA-290No lawful route
SecretinFDA-approved
ThymulinNo lawful route
L-carnosineNo lawful route
BPC-157PCAC-recommended · pending
MOTS-cPCAC-recommended · pending
TB-500PCAC-recommended · pending
KPVPCAC-recommended · pending
SemaxPCAC-recommended · pending
EpitalonPCAC-recommended · pending
DSIPNo lawful route
Melanotan IINo lawful route
LL-37No lawful route
DihexaNo lawful route
PEG-MGFNo lawful route
CJC-1295Nomination withdrawn
IpamorelinNomination withdrawn
AOD-9604Nomination withdrawn
Thymosin alpha-1Nomination withdrawn
SelankNomination withdrawn
CerebrolysinNo lawful route
RetatrutideNo lawful route